Answers are grounded in this paper and cite their sources.
Multiple Myeloma (MM) is characterized by growth and proliferation of clonal plasma cells in the bone marrow (BM), and these plasma cells depend heavily on this BM microenvironment. In a subset of patients, the myeloma cells can spread hematogenously to soft tissues and these extramedullary myeloma (EM) lesions may be found in up to 30% of MM patients, the majority occurring during the course of the disease. 1 When restricting the definition of EM lesions to infiltration of soft tissue only and excluding the bone-related plasmacytomas, the prognosis is dismal with an overall survival of less than 6 months. 1 , 2 It has been suggested that the incidence of EM relapses is increasing, possibly due to novel treatments or allogeneic stem cell transplantation. 3 Therefore novel therapeutic interventions are warranted. Molecular and DNA sequencing studies have revealed that MM is a genetically complex and heterogeneous disease, 4 , 5 which demonstrated that molecular events in MM are not attained in a linear manner, but show intraclonal heterogeneity. Each subclone may carry novel mutations, which can influence drug sensitivity. Possibly due to these impediments, little progress had been made thus far in specific therapeutic targeting of oncogenic mutations in MM. An illustrative example of a successful targeted therapy is the treatment of a MM patient carrying a BRAFV600 mutation and EM disease with BRAF inhibitor vermurafenib. 6 However, the frequency of these BRAFV600E mutations is low: around 8.5% in EM and around 4% in general MM population. 5 , 6 Another pitfall in the development of more effective treatment for relapsed EM patients is the lack of knowledge of the exact pathogenic or molecular mechanisms of the transition to EM and the independency of the BM. One of the suggested mutations involved in this transition is RAS mutations, since RAS mutations were found in three out of six EM samples, which were not detectable in the matched BM samples. 7
No takes yet. Share an insight, caveat, or question.
Haart et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: